- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00208910
Muscle Relaxation Therapy With Odorant Cue
November 8, 2013 updated by: Emory University
A Study of Enhancement of Progressive Muscle Relaxation Therapy for Generalized Anxiety Disorder Through Use Of An Odorant Cue.
A novel procedure for generalized anxiety disorder where an odorant cue is paired with the state of deep relaxation during training.
It is hypothesized that by smelling the odor in an anxiety-provoking situation, the patient will more easily invoke a state of relaxation, providing greater relief from the distressing tension and worry that characterize GAD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
We hypothesize that by presenting a novel odor to a patient in a state of deep relaxation, the odor will serve as a conditioned inhibitory stimulus, or safety signal, in anxiety-provoking situations.
With the odor serving as a contextual cue for the state of relaxation.
Study Type
Interventional
Enrollment
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Emory University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- GAD without a comorbid active major psychiatric disorder.
- GAD must be the primary active psychiatric disorder.
- GAD determined via the Mini International Neuropsychiatric Interview (MINI).
Exclusion Criteria:
- Significant medical illness that might interfere with the relaxation therapy or with training using the odorant.
- Actively abusing alcohol.
- Illicit substances.
- Currently using rapid-acting anxiolytic agents (e.g. benzodiazepines, hydroxyzine).
- Started an antidepressant, antipsychotic or mood stabilizing agent within three months of screening visit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
PSWQ
|
Secondary Outcome Measures
Outcome Measure |
---|
HAM-A
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Philip T Ninan, MD, Emory University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2003
Study Completion
May 1, 2005
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
November 11, 2013
Last Update Submitted That Met QC Criteria
November 8, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0860-2003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada
Clinical Trials on Odorant Cue
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Completed
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Indiana UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Recruiting
-
Brigham and Women's HospitalNational Institute on Aging (NIA)CompletedRheumatic Diseases | Lupus Erythematosus, Systemic | Adherence, Medication | GoutUnited States
-
Boston University Charles River CampusRecruiting
-
University of SalfordUniversity of Nottingham; University of Birmingham; Stroke Research Network; University...Completed
-
Marco LeytonActive, not recruitingTobacco Use | Addiction Nicotine | Cigarette SmokingCanada
-
University of LeedsRecruiting
-
VU University of AmsterdamStrolll, LtdCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown